2014 Jun 12. [Epub ahead of print]
Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa.
de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, Machado S, Arias-Carrión O, Nardi AE, Silva AC1.
Author information
Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this work is to review the animal study articles using CBD as an anxiolytic-like and antidepressant-like compound. Articles were identified using the major electronic databases, including the ISI Web of Knowledge, Scielo, PubMed and PsycINFO, combining the terms “cannabidiol”, “antidepressant-like” and “anxiolytic-like”. As languages for this search, we used Portuguese and English. Animal study articles were primarily included. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and anti-depressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuro-receptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor, except by on that it was not clear.
PMID: 24923339 [PubMed – as supplied by publisher]
